Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.85 EUR | +1.65% |
|
-20.26% | -12.74% |
06-27 | ADRs End Flat; Alarum Technologies Climbs 26% | DJ |
06-27 | Wall Street Set to Open Marginally Lower Thursday as Investors Parse Bullish Economic Data | MT |
Summary
- On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- According to Standard & Poor's' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- Low profitability weakens the company.
- Based on current prices, the company has particularly high valuation levels.
- The company appears highly valued given the size of its balance sheet.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
Ratings chart - Surperformance
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-12.74% | 280M | - | ||
+38.65% | 39.36B | A | ||
-8.62% | 38.52B | B | ||
+26.95% | 30.74B | B | ||
+10.74% | 25.92B | B- | ||
-13.50% | 26.03B | C | ||
+44.87% | 14.13B | B+ | ||
+34.36% | 12.73B | C+ | ||
-7.14% | 11.29B | B+ | ||
-12.61% | 10.64B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- IMM Stock
- YP1A Stock
- Ratings Immutep ADR